Contenu du site

 Improving cancer therapies is of paramount importance as cancer remains one of the leading causes of death. Taxanes such as Paclitaxel (PTX) are considered essential chemotherapeutics for the treatment of solid tumors. However, commercial PTX formulations such as Taxol are associated with adverse drug toxicities. PTX formulations have been explored as they could increase efficacy and have improved pharmacokinetic (PK) properties. Despite great enthusiasm for drug-loaded anticancer nanocarriers (e.g., liposomes, nanoparticles, micelles), their bench-to-bedside translation is not straightforward. Thus, significant rethinking of drug delivery from nanocarriers seems inescapable. In the context, Julien Nicolas’ laboratory has developed a new PTX delivery system (i.e., PTX-PAAm) that is simple, efficient, comfortable for the patient and significantly less costly. This PTX-loaded nanoassemblies can be administered subcutaneously to enable self-administration and boost the development of at-home cancer chemotherapy. First in vivo results are very promising but optimal dose regimen still need to be defined. Your work will be to finalize a PK/PD model using mice pharmacokinetic data, Monolix Software and R programming and determine the optimal administration scheme for further preclinical studies in the development of this novel PTX-PAAm conjugate. 

 Knowledge in pharmacokinetics (non-compartmental, PK/PD, PB-PK), nanomedicine and oncology Python/R programming skills Monolix® software 

 This project is part of an ERC carried by Dr. Julien Nicolas (Institut Galien Paris Saclay UMR CNRS 8612). Applicants should be at least at the master level (5th year of studies). To apply, please send your resume, cover, and reference letters to anne.rodallec@univ-amu.fr, copied to florence.gattacceca@univ-amu.fr and sebastien.benzekry@inria.fr